Wolbachia-carrying Ae.aegypti mosquitoes

PreclinicalBiologic

Wolbachia-carrying Ae.aegypti mosquitoes is one of 53 biologic programs targeting Viral Disease. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Viral DiseaseActive, not recruiting

Viral DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Viral Disease

#DrugCompanyPhaseTrials

Tivicay

Cabenuva

Tyzeka

Hepsera

Vemlidy

Viread

Vistide

Incivek

Vertex Pharmaceuticals

Ziagen

Sunlenca

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Viral Disease1 trial

Impact of Wolbachia Deployment on Arboviral Disease Incidence in Medellin and Bello, Colombia

Completed·UUniversidad de Antioquia··NCT03631719·834 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Wolbachia-carrying Ae.aegypti mosquitoes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Wolbachia-carrying Ae.aegypti mosquitoes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Wolbachia-carrying Ae.aegypti mosquitoes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universidad de Antioquia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversidad de Antioquia

Wolbachia-carrying Ae.aegypti mosquitoes

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Viral Disease1 trial

References

Drug Info

Quick Facts

Related News